Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ulcerative colitis.

Richard J Farrell1, Mark A Peppercorn

  • 1Division of Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. rfarrell@caregroup.harvard.edu

Lancet (London, England)
|February 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sociodemographic variables as predictors of adverse outcome in SARS-CoV-2 infection: an Irish hospital experience.

Irish journal of medical science·2020
Same author

Using Adalimumab to Treat Autoimmune Enteropathy.

ACG case reports journal·2020
Same author

Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?

The New England journal of medicine·2019
Same author

Insights into the treatment of inflammatory bowel disease in pregnancy.

Therapeutic advances in gastroenterology·2019
Same author

Immunosuppressive therapies for inflammatory bowel disease.

World journal of gastroenterology·2014
Same author

Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy.

Gastroenterology clinics of North America·2012
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Ulcerative colitis, an inflammatory bowel disease, may stem from environmental triggers in genetically prone individuals. Probiotics show promise as an innovative treatment for this chronic condition.

Area of Science:

  • Gastroenterology
  • Immunology
  • Microbiology

Background:

  • Ulcerative colitis is a chronic inflammatory condition affecting the rectum and colon.
  • Current understanding suggests a loss of tolerance to gut flora in genetically susceptible individuals, triggered by environmental factors.
  • Despite advances in management, innovative treatments for ulcerative colitis remain limited.

Purpose of the Study:

  • To review the current understanding of ulcerative colitis etiology and treatment landscape.
  • To explore potential novel therapeutic strategies for ulcerative colitis.
  • To assess the promise of probiotics as an experimental treatment for ulcerative colitis.

Main Methods:

  • Literature review of studies on intestinal inflammation in humans and animals.

Related Experiment Videos

  • Analysis of clinical data regarding biological agents for ulcerative colitis.
  • Evaluation of controlled clinical trials investigating experimental and traditional agents, including probiotics.

    • Main Results:

    • Ulcerative colitis pathogenesis likely involves environmental factors exacerbating immune responses to normal gut microbiota.
    • Few clinical data exist for biological agents in ulcerative colitis compared to Crohn's disease.
    • Probiotics have emerged as the most promising among investigated experimental agents.

    Conclusions:

    • Ulcerative colitis is a complex disease with multifactorial origins.
    • There is a need for innovative treatments beyond current management strategies.
    • Probiotics represent a promising avenue for future ulcerative colitis therapy.